白血病诱导的TIM-3+CD4+骨髓T细胞功能障碍增加儿童B前体ALL复发风险
该研究分析100例儿童前体B细胞急性淋巴细胞白血病(ALL)患者的骨髓T细胞,发现ALL与CD4+晚期表型及早期CD8+ T细胞缺失相关。CD4+骨髓T细胞上抑制性耗竭标志物TIM-3高频率增加复发风险(RFS 94.6%/70.3%),多因素分析证实其风险比接近MRD(7.1 vs 8.0)。CD200/TIM-3信号而非PD-1/PD-L1是T细胞功能障碍机制。
要点
- 初诊时CD4+骨髓T细胞TIM-3高表达者复发风险增加7.1倍,接近MRD的8.0倍。
- ALL患者骨髓CD4+ T细胞呈晚期表型,早期CD8+ T细胞减少。
- CD200/TIM-3信号介导T细胞抗白血病功能障碍,非PD-1/PD-L1。
核心结论
- TIM-3介导的骨髓T细胞与白血病细胞相互作用是儿童B系ALL复发的强风险因素。
研究设计与样本
- 基于100例儿童前体B细胞ALL患者骨髓T细胞的分析,并结合CRISPR/Cas9介导的TIM-3敲除与过表达实验验证。
主要发现
- ALL与CD4+晚期表型及早期CD8+ T细胞缺失相关。
- CD4+骨髓T细胞TIM-3表达增加复发风险,RFS为94.6%/70.3%。
- 多因素分析显示TIM-3表达风险比接近MRD(7.1 vs 8.0),高频率TIM-3+CD4+骨髓T细胞患者复发风险增加7.1倍。
- TIM-3+CD4+骨髓T细胞在过表达CD200的ALL中增加,导致抗白血病T细胞应答功能障碍。
临床怎么用
- 初诊时检测骨髓CD4+ T细胞TIM-3表达可能辅助评估儿童B-ALL复发风险。
- CD200/TIM-3信号轴可作为未来免疫治疗的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interaction of malignancies with tissue-specific immune cells has gained interest for prognosis and intervention of emerging immunotherapies. We analyzed bone marrow T cells (bmT) as tumor-infiltrating lymphocytes in pediatric precursor-B cell acute lymphoblastic leukemia (ALL). Based on data from 100 patients, we show that ALL is associated with late-stage CD4+ phenotype and loss of early CD8+ T cells. The inhibitory exhaustion marker TIM-3 on CD4+ bmT increased relapse risk (RFS = 94.6/70.3%) confirmed by multivariate analysis. The hazard ratio of TIM-3 expression nearly reached the hazard ratio of MRD (7.1 vs. 8.0) indicating that patients with a high frequency of TIM-3+CD4+ bone marrow T cells at initial diagnosis have a 7.1-fold increased risk to develop ALL relapse. Comparison of wild type primary T cells to CRISPR/Cas9-mediated TIM-3 knockout and TIM-3 overexpression confirmed the negative effect of TIM-3 on T cell responses against ALL. TIM-3+CD4+ bmT are increased in ALL overexpressing CD200, that leads to dysfunctional antileukemic T cell responses. In conclusion, TIM-3-mediated interaction between bmT and leukemia cells is shown as a strong risk factor for relapse in pediatric B-lineage ALL. CD200/TIM-3-signaling, rather than PD-1/PD-L1, is uncovered as a mechanism of T cell dysfunction in ALL with major implication for future immunotherapies.
引用
- Blaeschke F, Willier S, Stenger D, et al. Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. Leukemia. 2020. PMID: 32203137. doi:10.1038/s41375-020-0793-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。